PDCD1 and plasma cell myeloma: These observations have led to various clinical trials aiming to block the interaction between PD-1 and PD-L1 using the monoclonal antibodies anti-PD-1 or anti-PD-L1 in several types of cancers (melanoma, gastric cancer, multiple myeloma)5.